A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer

BACKGROUND: The addition of bevacizumab to standard chemotherapy prolongs progression free survival in the first line treatment of epithelial ovarian cancer (EOC), but its cost/effectiveness is debated. We assessed the safety and activity of a lower dose of bevacizumab in pretreated advanced stage E...

Descripción completa

Detalles Bibliográficos
Autores principales: Defferrari, Carlotta, Campora, Sara, D'Amico, Mauro, Piccardo, Arnoldo, Biscaldi, Ennio, Rosselli, Daniela, Pasa, Ambra, Puntoni, Matteo, Gozza, Alberto, Gennari, Alessandra, Zanardi, Silvia, Lionetto, Rita, Bandelloni, Michela, DeCensi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408333/
https://www.ncbi.nlm.nih.gov/pubmed/22732001
http://dx.doi.org/10.1186/1757-2215-5-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408333/
https://www.ncbi.nlm.nih.gov/pubmed/22732001
http://dx.doi.org/10.1186/1757-2215-5-17

Ejemplares similares